R S Goland1, S Jozak, I Conwell. 1. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032.
Abstract
OBJECTIVE: Our purpose was to clarify whether placental corticotropin-releasing hormone regulates pituitary-adrenal function in human pregnancy. STUDY DESIGN: We examined the relationship between maternal plasma corticotropin-releasing hormone concentrations and levels of pituitary-adrenal hormones at 5-week intervals in 21 uncomplicated term pregnancies. RESULTS: Maternal plasma corticotropin-releasing hormone concentrations rose significantly from 115 +/- 45 pg/ml at 11 to 15 weeks to 4346 +/- 754 pg/ml at 36 to 40 weeks (p < 0.001). Afternoon plasma corticotropin concentrations also rose significantly from 8.8 +/- 2.8 pg/ml to 18 +/- 2.6 pg/ml (p < 0.005). Urinary free cortisol concentrations rose from 54.8 +/- 7.3 micrograms per 24 hours to 111 +/- 8.7 micrograms per 24 hours (p < 0.005). Maternal dehydroepiandrosterone sulfate levels fell from 102 +/- 14 micrograms/dl to 63.8 +/- 7.1 micrograms/dl (p < 0.005). Maternal plasma corticotropin-releasing hormone was significantly correlated with afternoon plasma corticotropin concentrations (r = 0.6, p < 0.0001) and with urinary free cortisol concentrations (r = 0.04, p < 0.01). CONCLUSIONS: Similar modest elevations of corticotropin and cortisol, as occur in pregnancy, have been reported in vitro and in vivo studies of long-term administration of corticotropin-releasing hormone. Our findings support the concept that placental corticotropin-releasing hormone modulates pituitary-adrenal function in pregnancy.
OBJECTIVE: Our purpose was to clarify whether placental corticotropin-releasing hormone regulates pituitary-adrenal function in human pregnancy. STUDY DESIGN: We examined the relationship between maternal plasma corticotropin-releasing hormone concentrations and levels of pituitary-adrenal hormones at 5-week intervals in 21 uncomplicated term pregnancies. RESULTS: Maternal plasma corticotropin-releasing hormone concentrations rose significantly from 115 +/- 45 pg/ml at 11 to 15 weeks to 4346 +/- 754 pg/ml at 36 to 40 weeks (p < 0.001). Afternoon plasma corticotropin concentrations also rose significantly from 8.8 +/- 2.8 pg/ml to 18 +/- 2.6 pg/ml (p < 0.005). Urinary free cortisol concentrations rose from 54.8 +/- 7.3 micrograms per 24 hours to 111 +/- 8.7 micrograms per 24 hours (p < 0.005). Maternal dehydroepiandrosterone sulfate levels fell from 102 +/- 14 micrograms/dl to 63.8 +/- 7.1 micrograms/dl (p < 0.005). Maternal plasma corticotropin-releasing hormone was significantly correlated with afternoon plasma corticotropin concentrations (r = 0.6, p < 0.0001) and with urinary free cortisol concentrations (r = 0.04, p < 0.01). CONCLUSIONS: Similar modest elevations of corticotropin and cortisol, as occur in pregnancy, have been reported in vitro and in vivo studies of long-term administration of corticotropin-releasing hormone. Our findings support the concept that placental corticotropin-releasing hormone modulates pituitary-adrenal function in pregnancy.
Authors: Laurence R Gesquiere; Memuna Khan; Lili Shek; Tim L Wango; Emmanuel O Wango; Susan C Alberts; Jeanne Altmann Journal: Horm Behav Date: 2008-04-24 Impact factor: 3.587
Authors: M Hill; A Pařízek; P Šimják; M Koucký; K Anderlová; H Krejčí; D Vejražková; L Ondřejíková; A Černý; R Kancheva Journal: Physiol Res Date: 2021-12-30 Impact factor: 2.139
Authors: Rogier A M Quax; Yaël A de Man; Jan W Koper; Elisabeth F C van Rossum; Sten P Willemsen; Steven W J Lamberts; Johanna M W Hazes; Radboud J E M Dolhain; Richard A Feelders Journal: Arthritis Res Ther Date: 2012-08-13 Impact factor: 5.156
Authors: Michael Schneider; Anne Engel; Peter A Fasching; Lothar Häberle; Elisabeth B Binder; Franziska Voigt; Jennifer Grimm; Florian Faschingbauer; Anna Eichler; Ulf Dammer; Dirk Rebhan; Manuela Amann; Eva Raabe; Tamme W Goecke; Carina Quast; Matthias W Beckmann; Johannes Kornhuber; Anna Seifert; Stefanie Burghaus Journal: Biomed Res Int Date: 2014-03-12 Impact factor: 3.411